The historical rank and industry rank for Neuland Laboratories's FCF Margin % or its related term are showing as below:
NSE:NEULANDLAB'
s FCF Margin % Range Over the Past 10 Years
Min: -23.94 Med: 1.1 Max: 14.74
Current: -2.49
During the past 13 years, the highest FCF Margin % of Neuland Laboratories was 14.74%. The lowest was -23.94%. And the median was 1.10%.
NSE:NEULANDLAB's FCF Margin % is ranked worse than 63.67% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs NSE:NEULANDLAB: -2.49
Neuland Laboratories FCF Margin % Related Terms
Neuland Laboratories FCF Margin % Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neuland Laboratories and its competitors. According to the industry distribution chart, Neuland Laboratories ranks #610 out of 958 companies in the Drug Manufacturers industry, placing it in the top 63.7%.
Is Neuland Laboratories' FCF Margin % too high?
Neuland Laboratories' current FCF Margin % is 0.00%. Based on the distribution chart, Neuland Laboratories ranks #610 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #610 out of 958 companies for FCF Margin %. This places Neuland Laboratories in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,462.93, compared to a current price of ₹17,961.00 — trading 9.1% above its estimated fair value. The current FCF Margin % is 0.00%. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹17,961.00 is trading 9.1% above its estimated GF Value™ of ₹16,462.93.
GuruFocus considers Neuland Laboratories to be Fairly Valued.
Key valuation signals for NSE:NEULANDLAB:
FCF Margin %: 0.00%
GF Value™: ₹16,462.93 vs. price of ₹17,961.00 (9.1% above fair value)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
